Search

RU-2026112263-A - IL-4RA/TSLP ANTIBODIES AND THEIR APPLICATIONS

RU2026112263ARU 2026112263 ARU2026112263 ARU 2026112263ARU-2026112263-A

Inventors

  • СЮН, Яо
  • Ли, Ли
  • ЧЖОУ, Шуайсян
  • ЧЖУ, Мэнчжу
  • Фу, Цзе

Assignees

  • ФОРТВИТА БАЙОЛОДЖИКС (СИНГАПУР) ПТЕ. ЛТД.

Dates

Publication Date
20260505
Application Date
20241011
Priority Date
20231012

Claims (20)

  1. 1. An antigen-binding protein construct comprising a first antigen-binding domain that specifically binds to IL-4Ra and a second antigen-binding domain that specifically binds to TSLP.
  2. 2. The antigen-binding protein construct according to claim 1, wherein the first antigen-binding domain comprises a first variable region of the heavy chain (VH1) and a first variable region of the light chain (VL1); and the second antigen-binding domain comprises a second variable region of the heavy chain (VH2) and a second variable region of the light chain (VL2).
  3. 3. The antigen-binding protein according to claim 2, where
  4. the first heavy chain variable region (VH1) comprises complementarity determining regions (CDRs) 1, 2 and 3, wherein the CDR1 region of VH1 comprises an amino acid sequence that is at least 80% identical to the selected amino acid sequence of CDR1 of VH1, the CDR2 region of VH1 comprises an amino acid sequence that is at least 80% identical to the selected amino acid sequence of CDR2 of VH1, and the CDR3 region of VH1 comprises an amino acid sequence that is at least 80% identical to the selected amino acid sequence of CDR3 of VH1; and
  5. the first variable region of the light chain (VL1) comprises CDRs 1, 2 and 3, wherein the CDR1 region of VL1 comprises an amino acid sequence that is at least 80% identical to the selected amino acid sequence of CDR1 of VL1, the CDR2 region of VL1 comprises an amino acid sequence that is at least 80% identical to the selected amino acid sequence of CDR2 of VL1, and the CDR3 region of VL1 comprises an amino acid sequence that is at least 80% identical to the selected amino acid sequence of CDR3 of VL1,
  6. where the selected amino acid sequences of CDRs 1, 2 and 3 of VH1, the selected amino acid sequences of CDRs 1, 2 and 3 of VL1 are one of the following:
  7. (1) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 1, 2, 3, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 4, 5, 6, respectively;
  8. (2) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 11, 12, 3, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 13, 14, 15, respectively;
  9. (3) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 18, 19, 3, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 20, 21, 22, respectively;
  10. (4) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 25, 26, 3, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 27, 28, 29, respectively;
  11. (5) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 32, 19, 3, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 33, 34, 6, respectively;
  12. (6) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 84, 2, 3, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 4, 5, 6, respectively;
  13. (7) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 85, 12, 3, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 13, 14, 15, respectively;
  14. (8) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 85, 19, 3, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 20, 21, 22, respectively;
  15. (9) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 85, 26, 3, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 27, 28, 29, respectively;
  16. (10) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 85, 19, 3, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 33, 34, 6, respectively;
  17. (11) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 87, 88, 89, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 90, 91, 92, respectively;
  18. (12) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 93, 94, 95, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 96, 97, 98, respectively;
  19. (13) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 99, 100, 101, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 102, 103, 104, respectively;
  20. (14) selected amino acid sequences of CDRs 1, 2, 3 of VH1 are shown as SEQ ID NO: 105, 106, 107, respectively, and selected amino acid sequences of CDRs 1, 2, 3 of VL1 are shown as SEQ ID NO: 108, 109, 110, respectively;